Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease

Table 1 Clinical and biochemical characteristics of each group ^a

Characteristic	NAFLD+CHD (n = 189)	NAFLD (n = 242)	Control (n = 266)
Age, y	58.10 ± 6.95	57.7 ± 8.53	58.90 ± 5.53
BMI, kg/m²	25.69 ± 3.2^*@	26.76 ± 2.82^*	23.65 ± 3.50
FPG, mmol/L	5.81 ± 1.81^*@	5.00 ± 1.35	4.85 ± 1.55
ALT, U/L	30.23 ± 2.80^*	34.56 ± 26.27^*	22.47 ± 21.14
AST, U/L	45.73 ± 70.71^*@	28.45 ± 21.49^*	22.52 ± 11.84
TC, mmol/L	5.22 ± 1.17	5.48 ± 0.83^*	5.10 ± 1.17
TG, mmol/L	2.00 ± 1.07^*	1.92 ± 1.31^*	1.52 ± 1.10
LDL, mmol/L	3.09 ± 1.06	3.26 ± 0.59	3.15 ± 0.73
HDL, mmol/L	1.03 ± 0.28^*@	1.23 ± 0.21	1.29 ± 0.38

Abbreviations: NAFLD non-alcoholic fatty liver disease, CHD coronary heart disease, BMI body mass index, FPG fasting plasma glucose, TC total cholesterol, TG triglyceride, LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, AST aspartate aminotransferase, ALT alanine aminotransferase
* Compared with the control group, P < 0.05; ^@ compared with NAFLD group, P < 0.05
^aData are presented as mean ± SD

ISSN: 1476-511X